Semaglutide vs Liraglutide Demonstrates Superior 1-Year Weight …
WEB15 hours ago · At 1 year, the mean percentage weight reduction was significantly greater with semaglutide (-5.1%) compared with liraglutide (-2.2%; P <.001). Patients with obesity achieved greater weight loss (-5.9%) than those with type 2 diabetes (-3.2%; P <.001). Of the total cohort, 40.7% maintained persistent medication coverage at 1 year, with higher persistence for semaglutide users (45.8%) compared ...
FDA Approves First Treatment to Reduce Risk of Serious Heart …
WEBToday, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults...
Obesity drug Wegovy cut risk of serious heart problems by 20%: …
WEBNov 11, 2023 · The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients. The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or …
FDA Approves New Drug Treatment for Chronic Weight …
WEBFDA approves Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Two-year effects of semaglutide in adults with overweight or obesity …
WEBOct 10, 2022 · In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo.
Long-term weight loss effects of semaglutide in obesity without ...
WEBMay 13, 2024 · The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) studied patients with established CVD and overweight or obesity but without diabetes.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
WEBFeb 10, 2021 · In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
Semaglutide and Cardiovascular Outcomes in Obesity without …
WEBNov 11, 2023 · In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the...
Semaglutide vs Tirzepatide for Weight Loss in Adults With …
WEBThis Medical News article is an interview with Robert Gabbay, MD, PhD, the American Diabetes Association’s chief scientific and medical officer. ... Design, Setting, and Participants In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic ...
Weight loss and cardiovascular disease risk outcomes of semaglutide…
WEBFeb 1, 2024 · Semaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.